Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-EBO and MVA-EbolaZ Prime-Boost Vaccine in Healthy Adults in Mali
NCT02368119Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cAd3-EBO and MVA-EbolaZ in Ebola virus disease (EVD) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Solicited Local Reactogenicity and Solicited Systemic Reactogenicity. Started Mar 2015; status: completed.
02
Drugs
cAd3-EBOMVA-EbolaZ
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02368119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368119.